Phase II Study of Ruxolitinib (INCB018424) in Patients With PSTAT3+ Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 25 Nov 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Jul 2014 Planned primary completion date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
- 08 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.